Friday, December 11th, 6:45AM-7:45 AM CDT
Ernest N. Morial Convention Center
900 Convention Center Blvd
New Orleans, LA 70130
Room: R06-R09
Friday Satellite Symposium on B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice , preceding the 68th ASH Annual Meeting and Exposition.
Learn from Leaders | Connect with Peers
Hematology Dialogues™
An Early Bite of ITP
Beignets, Coffee & Clinical Insights!
As novel B-cell–directed, mechanism-based therapies reshape the ITP treatment landscape, clinicians need practical guidance on integrating these agents to achieve sustained response and improve long-term outcomes. Delivered in MLI’s case-driven, interactive Dialogues™ format, this program helps hematologists/oncologists, pediatric hematologists, nurses, nurse practitioners, physician associates, and pharmacists translate emerging evidence into real-world ITP care—informed directly by input from key opinion leaders, clinicians, and patients living with ITP.
Reserve Your Seat – Enroll Today!
Meet Our Faculty
David J. Kuter, MD, DPhil
Physician at Massachusetts General Hospital & Professor of Medicine at Harvard Medical School
Boston, MA, US
Ronak H. Mistry, DO
Assistant Professor of Clinical Medicine, Perelman School of Medicine, University of Pennsylvania
Philadelphia, PA, US
Cindy Neunert, MD, MSCS
Section Head, Columbia University Irving Medical Center
New York, NY, USA
In-Person & Virtual Registration
Registration for this program does not constitute registration for the ASH 2026 Annual Meeting. You must complete the registration separately for the annual meeting.
If you’re unable to attend in-person, this ASH session will also be available via live stream on our social channels and via Zoom.
Learners can still attend and earn credit for FREE if you join the session via the live stream options provided.
This activity is intended for hematologists/oncologists, pediatric hematologists, nurses, NPs, PAs, pharmacists, fellows, and payers.
After completing this activity, the participant should be better able to:
- Explain how novel agents targeting B-cell–driven pathways within current treatment algorithms for patients with ITP
- Apply evidence-based sequencing strategies to transition from corticosteroids and optimize second- and later-line therapy selection in relapsed or refractory ITP
- Incorporate durability metrics, time-to-treatment-failure data, and long-term disease control goals into therapeutic decision-making for patients with ITP
- Implement best practices for shared decision-making to optimize patient-centered outcomes in ITP care settings
- Introduction
- Treatments for ITP: The B-Cell-Driven Approach
- Evidence-based Sequencing in ITP
- Moving Away From Short-Term Platelet Thresholds As the Sole Focus of Treatment Decisions
- Making Shared Decision-Making a Priority in ITP
- Conclusion
This activity is provided by MLI, in collaboration with Platelet Disorders Support Association
Accreditation, Support and Credit
In support of improving patient care, Medical Learning Institute Inc is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Medical Learning Institute Inc (MLI) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MOC Statement
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Participation information will be shared through the ACCME’s Program and Activity Reporting System (PARS).
For Physicians requesting MOC credit, the post-test and evaluation are required in their entirety as well as your ABIM ID number, DOB (MM/DD), and a score of 70% or higher is needed to obtain MOC credit.
Notice to Diplomates: MLI will report any claimed MOC/Lifelong Learning points to the appropriate Board within 4 weeks of completing the activity. Please ensure that you have provided your Board ID number and MMDD of birth.
EBAH
Medical Learning Institute Inc is an accredited CME-CPD provider by the European Board for Accreditation in
Hematology (EBAH).
This educational activity has been submitted to EBAH for review. Final EBAH CME-CPD credits information will be provided to learners prior to the live activity.
PA
Pharmacy
Medical Learning Institute Inc designates this application-based continuing education activity for 1.0 contact hours (0.1 CEUs) of the Accreditation Council for Pharmacy Education.
UAN: JA0007322-0000-26-028-L01-P
For Pharmacists, MLI will accept your completed evaluation form for up to 30 days and will report your participation to the NABP only if you provide your NABP e-Profile number and date of birth. Within 6 weeks, view your participation record at the NABP website: https://nabp.pharmacy/
Nursing Continuing Professional Development
Successful completion of this nursing continuing professional development activity will be awarded 1.0 contact hour and 0.5 contact hour in the area of pharmacology.
ILNA Coding
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
In the following ILNA subject areas: 1.0 point: Care Continuum (OCN, CBCN, CPHON, AOCNP, ROCN), Care of the Pediatric Hematology and Oncology Patient (CPHON), Disease Related Biology (CPHON), Oncology Nursing Practice (OCN), Pediatric Hematology Oncology Nursing Practice (CPHON), Symptom Management, Palliative Care, Supportive Care (OCN, CPHON, AOCNP), Treatment (AOCNP, CBCN, CPHON, OCN, ROCN)
The numerical value indicated on the document is the maximum amount of points that can be claimed in each subject area. The total amount of ILNA points claimed may not exceed the total amount of NCPD awarded from this course and may only apply to the credential each nurse is renewing.
Support Statement
This program is supported by independent educational grants from Novartis Pharmaceuticals Corporation.
Medical Learning Institute Inc is committed to providing high quality continuing education to healthcare professionals, as individuals and teams, with a protected space to learn, teach, and engage in scientific discourse free from influence from ineligible companies that may have an incentive to insert commercial bias into education. To that end, MLI requires faculty, presenters, planners, staff, and other individuals who are in a position to control the content of this CE activity to disclose all financial relationships they have had in the past 24 months with ineligible companies as defined by the ACCME, as related to the content of this CE activity, regardless of the amount or their view of the relevance to the education. All identified COI will be thoroughly vetted and mitigated according to MLI policy. These disclosures will be provided to learners prior to the start of the CE activity.
Faculty Disclosures
Planner/Presenter
David J. Kuter, MD, DPhil, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Expert Witness: Acelot, Alexion, Alpine, Amgen, argenx, Blackstone, Bristol Myers Squibb, Cardurion, Caremark, Chugai, Cyrus, Hengrui, Immunovant, ITP Support Association of the UK, Johnson & Johnson, Kyowa Kirin, Lilly, Medscape, Merck Sharp & Dohme, Novartis, Nurix, Nuvig, Ouro, PeerView, Physicians’ Education Resource, Pfizer, Platelet Disorder Support Association, Principia, Regeneron, Rigel, Risk Management Foundation, Sanofi, SEISMIC, Sobi, Takeda, Timberlyne, UCB, UpToDate, Vertex, Verve
Research Funding/Support: To institution: Novartis, Principia, Sanofi, Takeda
Other: Patent: UpToDate
Planner/Presenter
Ronak H. Mistry, DO, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor: X4 Pharmaceuticals (assisting with data extraction for research study)
Other: Stock Shares: Doximity
Planner/Presenter
Cindy Neunert, MD, MSCS, has a financial interest/relationship or affiliation in the form of:
Consultant/Advisor/Speaker: Janssen, Lilly (ended), Novartis (ended), Sanofi (ended), Sobi (ended), Takeda
Research Support/Funding: Novartis (ended)
Other: UpToDate (royalties not patent related)
Patient Voice
Ellen Rager has no relevant financial relationships with ineligible companies to disclose for this educational activity.
All of the relevant financial relationships of individuals for this activity have been mitigated.
Planning Committee and Content/Peer Reviewers
The planners and content/peer reviewers from Medical Learning Institute Inc, the accredited provider, do not have any relevant financial relationships to disclose with ineligible companies unless listed below.
Disclosure of Unlabeled Use
This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this CE activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the CE activity are those of the presenters and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this CE activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this CE activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing NCPD to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
Method of Participation
There are no fees for participating in or receiving credit for this CE activity, however, registration is required. In order to receive credit, learners must participate in the entire CE activity, complete the activity evaluation form and your certificate of credit will be generated. You will receive your certificate from Medical Learning Institute Inc.
For information on applicability and acceptance of continuing education credit for this CE activity, please consult your professional licensing board.
If you have questions regarding your certificate, please contact MLI at accreditation@mlieducation.org
About This Activity
Medical Learning Institute Inc is responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this CE activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of this activity is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of Medical Learning Institute Inc.
The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of Medical Learning Institute Inc or any of its partners, providers, and/or supporters.
Copyright © 2026 Medical Learning Institute Inc. All Rights Reserved.
This program is supported by independent educational grants from Novartis Pharmaceuticals Corporation.